Literature DB >> 3258140

Distinct biological and serological properties of human immunodeficiency viruses from the brain.

C Cheng-Mayer1, J A Levy.   

Abstract

Human immunodeficiency viruses from the brain can be distinguished from peripheral blood isolates by their ability to infect established human cell lines and their sensitivity to serum neutralization. Isolates from the brain and lymph nodes obtained from the same person displayed similar host range tropism and susceptibility to serum neutralization; however, the brain isolate infected macrophages more efficiently. These data suggest that brain isolates may represent a distinct subtype of the human immunodeficiency virus.

Entities:  

Mesh：

Year:  1988        PMID： 3258140     DOI： 10.1002/ana.410230716

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  64 in total

1.  Evolution of CXCR4-using human immunodeficiency virus type 1 SF162 is associated with two unique envelope mutations.

Authors:  Yana Kiselyeva; Rebecca Nedellec; Alejandra Ramos; Cristina Pastore; Leonid B Margolis; Donald E Mosier
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

2.  Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody.

Authors:  Florence M Brunel; Michael B Zwick; Rosa M F Cardoso; Josh D Nelson; Ian A Wilson; Dennis R Burton; Philip E Dawson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Anti-human immunodeficiency virus type 1 activities of U-90152 and U-75875 in human brain cell cultures.

Authors:  P K Peterson; G Gekker; S Hu; C C Chao
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

4.  β-Adrenergic receptor gene expression in HIV-associated neurocognitive impairment and encephalitis: implications for MOR-1K subcellular localization.

Authors:  Seth M Dever; Myosotys Rodriguez; Nazira El-Hage
Journal:  J Neurovirol       Date:  2016-07-11       Impact factor: 2.643

5.  Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

Authors:  M B Zwick; M Wang; P Poignard; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines.

Authors:  R S Kornbluth; K Kee; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

7.  Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons.

Authors:  Cornelia Speth; Thomas Schabetsberger; Iradji Mohsenipour; Gabriele Stöckl; Reinhard Würzner; Heribert Stoiber; Cornelia Lass-Flörl; Manfred P Dierich
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

8.  Primary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression.

Authors:  Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

9.  Chronic HIV-1 Tat and HIV reduce Rbfox3/NeuN: evidence for sex-related effects.

Authors:  Yun Kyung Hahn; Ruturaj R Masvekar; Ruqiang Xu; Kurt F Hauser; Pamela E Knapp
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

10.  Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.

Authors:  Hengyu Xu; Likai Song; Mikyung Kim; Margaret A Holmes; Zane Kraft; George Sellhorn; Ellis L Reinherz; Leonidas Stamatatos; Roland K Strong
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.